A Phase 1, Open-label Study to Evaluate the Safety and Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adult Participants
Latest Information Update: 18 Nov 2024
Price :
$35 *
At a glance
- Drugs Ceftibuten/ledaborbactam etzadroxil (Primary)
- Indications Bacterial infections; Urinary tract infections
- Focus Pharmacokinetics
- Sponsors VenatoRx Pharmaceuticals
- 11 Nov 2024 Status changed from not yet recruiting to recruiting.
- 05 Nov 2024 New trial record